Subgroup analysis of safety according to ICI therapy types
| Anti-PD (L)-1 Mono-Therapy | Anti-PD (L)-1 plus Chemotherapy | |||||||
|---|---|---|---|---|---|---|---|---|
| HIV (16) | HBV/HCV (30) | HIV (5) | HBVC/HCV(3) | |||||
| Any Grade irAEsN (%) | Grade ≥ 3 irAEsN (%) | AnyGrade irAEsN (%) | Grade≥3irAEsN (%) | Any Grade irAEsN (%) | Grade ≥ 3 irAEsN (%) | Any Grade irAEsN (%) | Grade ≥ 3 irAEsN (%) | |
| Total | 4 (25) | 3(19) | 13(43)a | 8(27)a | 1(20) | 0 | 1(33) | 1(33) |
| Colitis | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 1 |
| Hepatitis | 2 | 1 | 6 | 4 | 0 | 0 | 0 | 0 |
| Rash | 2 | 0 | 6 | 1 | 1 | 0 | 0 | 0 |
| Hypothyroidism | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Pneumonitis | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Arthritis | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Diabetes Mellitus | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Encephalitis | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
aTwo patients with baseline grade ≥ 2 hepatitis